Non-Alcoholic Fatty Liver Disease (NAFLD) is a significant and often overlooked health issue, particularly in the context of the global obesity epidemic. With a prevalence rate estimated at 25% worldwide, it is crucial for healthcare professionals to understand the complexities of diagnosing and treating this condition.
NAFLD is the most common chronic liver disease in Western countries, affecting up to one-third of the population. It is closely linked with metabolic syndrome, obesity, insulin resistance, and type 2 diabetes. The prevalence is increasing in parallel with the rise in obesity and type 2 diabetes, making it a significant public health concern.
Diagnosing NAFLD can be challenging due to its often asymptomatic nature. It is often identified incidentally during imaging studies or when liver enzyme levels are elevated. The gold standard for diagnosis is liver biopsy, but its invasive nature makes it unsuitable for population-wide screening. Non-invasive tools such as the NAFLD fibrosis score, FIB-4 index, and elastography are increasingly being used for risk stratification and diagnosis.
Currently, there are no approved pharmacological treatments for NAFLD. The mainstay of management is lifestyle modification, including weight loss, increased physical activity, and a healthy diet. In cases of advanced fibrosis or cirrhosis, patients may be referred for liver transplantation. Emerging therapies targeting various aspects of the disease process, such as insulin resistance, inflammation, and fibrosis, are under investigation.
NAFLD is an increasingly prevalent condition, requiring proactive identification and management by healthcare professionals. While diagnostic tools continue to evolve, treatment primarily involves lifestyle interventions. Ongoing research into pharmacological treatments promises new strategies for managing this significant public health issue.
1.
Chemo-Free Triplet Yields 68% Response Rate in Richter Transformation
2.
Can Fasting Around Chemo Improve Ovarian Cancer Outcomes?
3.
Chemo causes lasting physical decline in breast cancer survivors
4.
MRI-guided radiation therapy improves quality of life with fewer side effects in patients with localized cancer. JAMA
5.
BMI is linked to heart damage from chemotherapy in breast cancer patients.
1.
The Role of the Oncology Pharmacist: From Treatment to Trials and Beyond
2.
Rehabilitation Following Bone Marrow Functional Suppression: Clinical Strategies and Advances
3.
Unlocking the Potential of Cancer Antigen 19-9 for Early Detection
4.
Strategic Breakthroughs in Oncology in Clinical Decision-Making
5.
Targeted Approaches to Breast Cancer Liver Metastases: Surgery, Ablation, and Survival Insights
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
2.
Early warning sings of camcer that need medical attention
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
4.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
5.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation